12:53 PM EDT, 09/03/2025 (MT Newswires) -- Arcutis Biotherapeutics ( ARQT ) said Wednesday it has filed a supplemental new drug application with the US Food and Drug Administration to expand the indication of Zoryve cream 0.3% to treat plaque psoriasis in children as young as two.

Plaque psoriasis is the most common form of psoriasis in young children and presents with similar clinical features to those seen in adults, the company said.

Shares of the company were up over 1% in recent trading.

Price: 15.50, Change: +0.18, Percent Change: +1.17